N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, today provides an update on its collaboration with MedImmune, following the
N4 Pharma PLC (AIM:N4P) Filing of Patent
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which improves the delivery of existing drugs and novel vaccines and therapeutics, is pleased to announce the filing of its
N4 Pharma PLC (AIM:N4P) Nuvec® Update
Nuvec® Update N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, is pleased to provide an update on its Nuvec®
N4 Pharma Plc (AIM:N4P) Collaboration with MedImmune UK
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, announces that it has been awarded a feasibility grant from Innovate
N4 Pharma PLC (LON:N4P) Exercise of Warrants and Total Voting Rights
The Company announces that it has received an exercise notice for the exercise of 428,569 warrants over ordinary shares of 0.4p each at an exercise price of 8.5 pence per
N4 Pharma Plc (AIM:N4P) Warrants cash to be used to accelerate vaccine plans
13 Dec 2017: The Company announces that it has received an exercise notice for the exercise of 2,071,429 warrants over ordinary shares of 0.4p each at an exercise price of
N4 Pharma Plc (AIM:N4P) Admission to AIM/Interview with CEO
Summary: · Change of name to N4 Pharma Plc (formerly Onzima Ventures Plc) effective · £1.5 million (gross) raised by way of a placing of 21,428,571 New Ordinary Shares at 7p per
